Delpharm and Famar, two of the European leaders in contract manufacturing and development of medicines for pharmaceutical laboratories, have announced that they have entered into exclusive negotiations for the acquisition by Delpharm of five Famar manufacturing sites in Canada, France and the Netherlands.
The transaction involves the takeover of the French sites located in Orléans (Loiret), Aigle (Orne) and St-Rémy-sur-Avre (Eure-et-Loire), the Pointe-Claire site in Quebec and that of Bladel in the Netherlands. The group of 5 sites represents a turnover of €250M and more than 1,300 employees.
The binding offer submitted by Delpharm to Famar remains subject, amongst others, to the approval of the competition authority. The transaction is expected to be completed by early November.
Sébastien Aguettant, President of Delpharm said: “The acquisition of the 5 Famar sites constitutes an important step towards our goal to become the drug manufacturer of choice for our major French and foreign clients. We ambitiously welcome the teams of these 5 sites and we are happy that they will join the 3,300 employees in the 12 existing sites of Delpharm.’’
Patrick Puy, President of Famar said: “The Board of Directors has agreed that the offer proposed by Delpharm is in the best interest of the 5 sites and their employees. The completion of this transaction will allow these sites to enter into a new phase of sustainable and promising development.”
Delpharm is a European leader in contract manufacturing and development of medicines for pharmaceutical laboratories. It owns 12 manufacturing plants (nine in France, two in Italy and one in Belgium) providing the majority of dosage forms available on the market: tablets, syrups, bottles and vials.
Delpharm generates €500m in turnover and is wholly owned by its management.
For more information, please fill out the enquiry form attached to this page.